RaphaelEricSteinerMD

PubMed

• Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
  Pallawi Torka, Tatyana Feldman, Kerry J Savage, Nivetha Ganesan, Esther Drill
  Journal of Clinical Oncology. 2024-12-11
• Ultra-Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the Lung.
  Susan Y Wu, Penny Q Fang, Ahmed Fetooh, Gohar S Manzar, Kelsey L Corrigan
  Advances in Radiation Oncology. 2024-12-01
• Author Correction: Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.
  Shaojun Zhang, Vivian Changying Jiang, Guangchun Han, Dapeng Hao, Junwei Lian
  Nature Communications. 2024-10-07

Abstracts/Posters

• A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma
  Raphael E Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
  Raphael Eric Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell LymphomaRadiation Therapy Can be ...
  Raphael E Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCL
  Raphael Eric Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma
  Raphael E Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (_65 years) Patients with Mantle Cell Lymphoma (MCL) _ Results from a...
  Raphael Eric Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Cli...
  Raphael E Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)
  Raphael E Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
  Raphael Eric Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma...
  Raphael Eric Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements o...
  Raphael Eric Steiner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018